Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Exp Neurol. 2017 Aug 31;298(Pt A):104–111. doi: 10.1016/j.expneurol.2017.08.016

Figure 6. Effect of CXCR2 pepducin treatment on infarct size and neurological deficit after stroke.

Figure 6

Wild type mice on a C57BL/6J background received intravenous injection of CXCR2 pepducin (2.5 mg/kg) 3 hours before and 9 hours after stroke. (A) Representative MRI sections from untreated, control peptide and CXCR2 pepducin treated mice 24 h after transient (90-minute) MCA occlusion. (B) Infarct volume in the ipsilateral hemisphere and (C) neurological deficit in mice 24 hr after stroke. Data are expressed as mean ± SEM. n=6–7 per group.